ArticlePPAR research2008
Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer.
Article in PPAR research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 28 citations in OpenAlex.
- PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression.Journal for immunotherapy of cancer · 2023Article
- Review
- The Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome.Journal of clinical medicine · 2023Review
- Review
- Systems Modeling of Developmental Vascular Toxicity.Current opinion in toxicology · 2019Article
- StandardizedIranian journal of pharmaceutical research : IJPR · 2019Article
- Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention.Atherosclerosis · 2017Review
- Redox-dependent anti-inflammatory signaling actions of unsaturated fatty acids.Annual review of physiology · 2014Review
- A comparison of peroxisome proliferator-activated receptor-α agonist and antagonist on human umbilical vein endothelial cells angiogenesis.Advanced biomedical research · 2013Article
- Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival.Pathology oncology research : POR · 2012Article
- PPAR gamma, bioactive lipids, and cancer progression.Frontiers in bioscience (Landmark edition) · 2012Review
- PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials.PPAR research · 2012Article
- Anti-angiogenic action of PPARγ ligand in human umbilical vein endothelial cells is mediated by PTEN upregulation and VEGFR-2 downregulation.Molecular and cellular biochemistry · 2011Article
- BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011Article
- Correlation of Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) and Retinoid X Receptor-alpha (RXR-alpha) expression with clinical risk factors in patients with advanced carotid atherosclerosis.Medical science monitor : international medical journal of experimental and clinical research · 2011Article
- Peroxisome proliferator-activated receptor-γ in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.Journal of cancer research and clinical oncology · 2011Article
- Methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate (CDODA-Me), a derivative of glycyrrhetinic acid, functions as a potent angiogenesis inhibitor.The Journal of pharmacology and experimental therapeutics · 2010Article
- Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review.Clinical medicine insights. Endocrinology and diabetes · 2010Article
- Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.PPAR research · 2010Article
- Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) has currently been considered as molecular target for the treatment of human metabolic disorders. Experimental data from in vitro cultures, animal models, and clinical trials have shown that PPAR-gamma ligand activation regulates differentiation and induces cell growth arrest and apoptosis in a variety of cancer types. Tumor angiogenesis constitutes a multifaceted process implicated in complex downstream signaling pathways that triggers tumor growth, invasion, and metastasis. In this aspect, accumulating in vitro and in vivo studies have provided extensive evidence that PPAR-gamma ligands can function as modulators of the angiogenic signaling cascade. In the current review, the crucial role of PPAR-gamma ligands and the underlying mechanisms participating in tumor angiogenesis are summarized. Targeting PPAR-gamma may prove to be a potential therapeutic strategy in combined treatments with conventional chemotherapy; however, special attention should be taken as there is also substantial evidence to support that PPAR-gamma ligands can enhance angiogenic phenotype in tumoral cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.